Insider Buying: Septerna, Inc. (NASDAQ:SEPN) CFO Purchases $21,750.30 in Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie acquired 3,718 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were purchased at an average price of $5.85 per share, with a total value of $21,750.30. Following the completion of the acquisition, the chief financial officer now owns 40,000 shares of the company’s stock, valued at $234,000. This represents a 10.25 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Septerna Stock Performance

Septerna stock opened at $6.47 on Friday. The stock’s fifty day simple moving average is $16.08. Septerna, Inc. has a one year low of $4.17 and a one year high of $28.99.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Wells Fargo & Company lowered Septerna from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $43.00 to $14.00 in a report on Tuesday, February 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $50.00 target price on shares of Septerna in a research report on Tuesday, February 11th. TD Cowen assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a “buy” rating on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock.

Institutional Investors Weigh In On Septerna

Hedge funds and other institutional investors have recently made changes to their positions in the business. Avoro Capital Advisors LLC acquired a new stake in shares of Septerna in the fourth quarter valued at about $25,419,000. TRV GP V LLC acquired a new stake in shares of Septerna in the fourth quarter valued at about $142,337,000. TRV GP VI LLC acquired a new stake in shares of Septerna in the fourth quarter valued at about $72,191,000. Vanguard Group Inc. acquired a new stake in shares of Septerna in the fourth quarter valued at about $22,557,000. Finally, Corebridge Financial Inc. acquired a new stake in shares of Septerna in the fourth quarter valued at about $212,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.